Phase 3 RCT in 808 cisplatin-eligible adults with muscle-invasive bladder cancer: perioperative enfortumab vedotin-pembrolizumab vs neoadjuvant cisplatin-gemcitabine improved estimated 2-year EFS (79.4% vs 66.2%; HR 0.53) and OS; grade ≥3 AEs 75.7% vs 67.2%.
RCTn = 808
Galsky et al. Enfortumab Vedotin and Pembrolizumab in Cisplatin-Eligible Bladder Cancer